Literature DB >> 32278856

Targeting STAT3 in cancer and autoimmune diseases.

Tohid Gharibi1, Zohreh Babaloo2, Arezoo Hosseini1, Meghdad Abdollahpour-Alitappeh3, Vida Hashemi4, Faroogh Marofi5, Kazem Nejati6, Behzad Baradaran7.   

Abstract

Signal transducer and activator of transcription 3 (STAT3) is a transcription factor that is activated downstream of a broad range of receptors particularly interleukin-6 (IL-6) family. STAT3 is the key regulator of cell proliferation, survival and apoptosis and is constitutively activated in most human cancers, indicating that it can be an important potential therapeutic target for cancer treatment. STAT3 also has important roles in lymphocyte biology, regulation of immune responses and autoimmunity. Considering the vital role of STAT3 in tumor progression and autoimmunity, scientists have focused to develop small molecules that suppress STAT3 function. In this review, we firstly discussed the predominant role of STAT3 in cancer and autoimmune diseases. Subsequently, we discussed the efficacy and therapeutic potential of different STAT3 inhibitors in cancer and autoimmune diseases in preclinical studies and clinical trials offering an insight into novel approaches for development of new STAT3 inhibitors.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Autoimmune diseases; Cancer; STAT3; Small molecule inhibitors

Mesh:

Substances:

Year:  2020        PMID: 32278856     DOI: 10.1016/j.ejphar.2020.173107

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  16 in total

1.  Integrative multiomics analysis highlights immune-cell regulatory mechanisms and shared genetic architecture for 14 immune-associated diseases and cancer outcomes.

Authors:  Claire Prince; Ruth E Mitchell; Tom G Richardson
Journal:  Am J Hum Genet       Date:  2021-11-05       Impact factor: 11.043

Review 2.  Pediatric Inflammatory Multisystem Syndrome (PIMS) - Potential role for cytokines such Is IL-6.

Authors:  L Lacina; J Brábek; Š Fingerhutová; J Zeman; K Smetana
Journal:  Physiol Res       Date:  2021-04-30       Impact factor: 1.881

Review 3.  Coordinated regulation of immune contexture: crosstalk between STAT3 and immune cells during breast cancer progression.

Authors:  Jing Jin; Yi Li; Qijie Zhao; Yue Chen; Shaozhi Fu; JingBo Wu
Journal:  Cell Commun Signal       Date:  2021-05-06       Impact factor: 5.712

Review 4.  Protective Effect of Epigallocatechin-3-Gallate (EGCG) in Diseases with Uncontrolled Immune Activation: Could Such a Scenario Be Helpful to Counteract COVID-19?

Authors:  Marta Menegazzi; Rachele Campagnari; Mariarita Bertoldi; Rosalia Crupi; Rosanna Di Paola; Salvatore Cuzzocrea
Journal:  Int J Mol Sci       Date:  2020-07-21       Impact factor: 5.923

Review 5.  Inflammation-Driven Breast Tumor Cell Plasticity: Stemness/EMT, Therapy Resistance and Dormancy.

Authors:  Tamir Baram; Linor Rubinstein-Achiasaf; Hagar Ben-Yaakov; Adit Ben-Baruch
Journal:  Front Oncol       Date:  2021-01-26       Impact factor: 6.244

6.  Chidamide induces apoptosis in DLBCL cells by suppressing the HDACs/STAT3/Bcl‑2 pathway.

Authors:  Hongwei Zhang; Fenqing Chi; Keru Qin; Xiuli Mu; Lieyang Wang; Bin Yang; Yanli Wang; Min Bai; Zhenhua Li; Liping Su; Baofeng Yu
Journal:  Mol Med Rep       Date:  2021-03-02       Impact factor: 2.952

7.  Tea polyphenol EGCG inhibited colorectal-cancer-cell proliferation and migration via downregulation of STAT3.

Authors:  Ke-Wang Luo; Jun Xia; Bao-Hui Cheng; Han-Chao Gao; Li-Wu Fu; Xin-Le Luo
Journal:  Gastroenterol Rep (Oxf)       Date:  2020-12-03

8.  Prolactin Rescues Immature B Cells from Apoptosis-Induced BCR-Aggregation through STAT3, Bcl2a1a, Bcl2l2, and Birc5 in Lupus-Prone MRL/lpr Mice.

Authors:  Rocio Flores-Fernández; Angélica Aponte-López; Mayra C Suárez-Arriaga; Patricia Gorocica-Rosete; Alberto Pizaña-Venegas; Luis Chávez-Sanchéz; Francico Blanco-Favela; Ezequiel M Fuentes-Pananá; Adriana K Chávez-Rueda
Journal:  Cells       Date:  2021-02-04       Impact factor: 6.600

Review 9.  Contribution of STAT3 to the pathogenesis of COVID-19.

Authors:  Abdollah Jafarzadeh; Maryam Nemati; Sara Jafarzadeh
Journal:  Microb Pathog       Date:  2021-03-07       Impact factor: 3.848

Review 10.  A review of Dynamin 2 involvement in cancers highlights a promising therapeutic target.

Authors:  Delphine Trochet; Marc Bitoun
Journal:  J Exp Clin Cancer Res       Date:  2021-07-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.